scholarly journals Cardiovascular Presentation in Pheochromocytoma: What We Should be Aware

2022 ◽  
Vol 74 (1) ◽  
pp. 68-74
Author(s):  
Rizki Amalia ◽  
Ivana Purnama Dewi ◽  
Louisa Fadjri Kusuma Wardhani ◽  
Budi Susetio Pikir
Keyword(s):  
Adrenergic Receptors ◽  
Complete Resolution ◽  
Acute Coronary Syndromes ◽  
Ventricular Arrhythmias ◽  
Clinical Presentation ◽  
Myocardial Dysfunction ◽  
Tumor Resection ◽  
Cardiovascular Disorders ◽  
Life Threatening ◽  
Coronary Syndromes

Pheochromocytoma is a catecholamine-producing tumor that although being a rare disease, it poses diagnostic problems because its clinical presentation often mimics certain diseases, including cardiovascular disorders. The effects of excessive catecholamine secretion cause a variety of cardiovascular presentations ranging from hypertension to life-threatening cases such as hypertensive emergency, shock, supraventricular or ventricular arrhythmias, pulmonary edema, and acute coronary syndromes. The principal medical treatment for pheochromocytoma is a blockade of adrenergic receptors. However, surgical or tumor resection often provides complete resolution of abnormal myocardial dysfunction or arrhythmias, so this approach remains the mainstay of treatment that should be performed as soon as the diagnosis of pheochromocytoma is established. As clinicians, we must be aware of the characteristics of the cardiovascular manifestations of pheochromocytoma to make an earlier diagnosis and more appropriate management.

scholarly journals Potential value for new diagnostic markers in the early recognition of acute coronary syndromes

CJEM ◽  
2006 ◽  
Vol 8 (01) ◽  
pp. 27-31 ◽  
Author(s):  
Giuseppe Lippi ◽  
Martina Montagnana ◽  
Gian Luca Salvagno ◽  
Gian Cesare Guidi
Keyword(s):  
Myocardial Ischemia ◽  
Acute Coronary Syndromes ◽  
Early Recognition ◽  
Myocardial Dysfunction ◽  
Acute Chest Pain ◽  
Diagnostic Approach ◽  
Time Of Arrival ◽  
New Era ◽  
Coronary Syndromes ◽  
New Biomarkers

ABSTRACTThe diagnostic approach to acute coronary syndromes (ACS) remains one of the most difficult and controversial challenges facing emergency physicians. In recent years, cardiac troponins have emerged as the biochemical “gold standard” for diagnosis of patients with acute chest pain, enhancing our ability to recognize ACS. Early diagnosis and treatment of myocardial ischemia improve patient outcomes, but conventional markers are often nondiagnostic at the time of arrival at the emergency department. Promising new biomarkers, which appear earlier after the onset of ischemia, are being studied and integrated into clinical practice. Some are markers of myocyte necrosis, but others, including ischemia-modified albumin and natriuretic peptides, detect myocardial ischemia and myocardial dysfunction. The aim of the present article is to review the diagnostic approach to ACS, focusing on recent literature describing novel biochemical markers. If ongoing and future studies confirm their role in probability-based models risk assessment, a new era in the diagnostic approach to ACS may be dawning.

scholarly journals Clinical presentation and short term outcome of acute coronary syndromes in native young saudi population

2012 ◽  
Vol 24 (4) ◽  
pp. 294
Author(s):  
Mushabab A. Al-Murayeh ◽  
Adel A. Al-Masswary ◽  
Mohamed D. Dardir ◽  
Mohamed S. Moselhy ◽  
Ali A. Youssef
Keyword(s):  
Acute Coronary Syndromes ◽  
Clinical Presentation ◽  
Saudi Population ◽  
Short Term ◽  
Term Outcome ◽  
Short Term Outcome ◽  
Coronary Syndromes

scholarly journals The major element of 1-year prognosis in acute coronary syndromes is severity of initial clinical presentation: Results from the French MONICA registries

2012 ◽  
Vol 105 (10) ◽  
pp. 478-488 ◽  
Author(s):  
Paul-Louis Vervueren ◽  
Meyer Elbaz ◽  
Aline Wagner ◽  
Jean Dallongeville ◽  
Jean-Bernard Ruidavets ◽  
...  
Keyword(s):  
Acute Coronary Syndromes ◽  
Clinical Presentation ◽  
Major Element ◽  
Coronary Syndromes

Spectrum of Acute Coronary Syndromes: History and Clinical Presentation in Relation to Sex and Age

Cardiology ◽  
2004 ◽  
Vol 102 (2) ◽  
pp. 67-76 ◽  
Author(s):  
Elisabeth Perers ◽  
Kenneth Caidahl ◽  
Johan Herlitz ◽  
Margaretha Sjölin ◽  
Björn W. Karlson ◽  
...  
Keyword(s):  
Acute Coronary Syndromes ◽  
Clinical Presentation ◽  
Coronary Syndromes

scholarly journals Ventricular arrhythmias in acute coronary syndromes-mechanisms and management

2017 ◽  
Vol 3 (1) ◽  
pp. 22-29 ◽  
Author(s):  
D. E. Thomas ◽  
N. Jex ◽  
A. R. Thornley
Keyword(s):  
Acute Coronary Syndromes ◽  
Ventricular Arrhythmias ◽  
Coronary Syndromes

scholarly journals Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS

2020 ◽  
Vol 41 (37) ◽  
pp. 3533-3545 ◽  
Author(s):  
Usman Baber ◽  
George Dangas ◽  
Dominick Joseph Angiolillo ◽  
David Joel Cohen ◽  
Samin Kumar Sharma ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
High Risk ◽  
Acute Coronary Syndromes ◽  
Clinical Presentation ◽  
Coronary Intervention ◽  
Secondary Outcome ◽  
Bleeding Events ◽  
Double Blind ◽  
Percutaneous Coronary ◽  
Coronary Syndromes

Abstract Aims  The aim of this study was to determine the effect of ticagrelor monotherapy on clinically relevant bleeding and major ischaemic events in relation to clinical presentation with and without non-ST elevation acute coronary syndromes (NSTE-ACS) among patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Methods and results  We conducted a pre-specified subgroup analysis of The Ticagrelor With Aspirin or Alone in High Risk Patients After Coronary Intervention (TWILIGHT) trial, which enrolled 9006 patients with high-risk features undergoing PCI with DES. After 3 months of dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin, 7119 adherent and event-free patients were randomized in a double-blind manner to ticagrelor plus placebo versus ticagrelor plus aspirin for 12 months. The primary outcome was Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding while the composite of all-cause death, myocardial infarction (MI), or stroke was the key secondary outcome. Among patients with NSTE-ACS (n = 4614), ticagrelor monotherapy reduced BARC 2, 3, or 5 bleeding by 53% [3.6% vs. 7.6%; hazard ratio (HR) 0.47; 95% confidence interval (CI) 0.36–0.61; P < 0.001) and in stable patients (n = 2503) by 24% (4.8% vs. 6.2%; HR 0.76; 95% CI 0.54–1.06; P = 0.11; nominal Pint = 0.03). Rates of all-cause death, MI, or stroke among those with (4.3% vs. 4.4%; HR 0.97; 95% CI 0.74–1.28; P = 0.84) and without (3.1% vs. 3.2%; HR 0.96; 95% CI 0.61–1.49; P = 0.85) NSTE-ACS were similar between treatment arms irrespective of clinical presentation (Pint = 0.96). Conclusion  Among patients with or without NSTE-ACS who have completed an initial 3-month course of DAPT following PCI with DES, ticagrelor monotherapy reduced clinically meaningful bleeding events without increasing ischaemic risk as compared with ticagrelor plus aspirin. The benefits of ticagrelor monotherapy with respect to bleeding events were more pronounced in patients with NSTE-ACS. Trial registration Clinicaltrials.gov identifier: NCT02270242.

scholarly journals Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey

2006 ◽  
Vol 27 (7) ◽  
pp. 789-795 ◽  
Author(s):  
Annika Rosengren ◽  
Lars Wallentin ◽  
Maarten Simoons ◽  
Anselm K Gitt ◽  
Solomon Behar ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Acute Coronary Syndromes ◽  
Clinical Presentation ◽  
Coronary Syndrome ◽  
Coronary Syndromes
Sign in / Sign up

Export Citation Format

Share Document